Successful treatment of tardive akathisia with moclobemide, a reversible and selective monoamine-oxidase-A inhibitor. A case study.

Abstract

Tardive akathisia (TA) is a well-documented side-effect of neuroleptic treatment. The underlying mechanism is poorly understood, and treatment is unsatisfactory. In this case report, TA that occurred in the course of a tardive dyskinesia (TD) was successfully treated with the monoamine-oxidase-A inhibitor moclobemide. With respect to the mechanism of action, it may be hypothesized that dopaminergic supersensitivity in the mesocortical region is counteracted by enhanced inhibition of primarily noradrenergic neurotransmission.

• Authors: D Ebert, J Demling
• Journal: Pharmacopsychiatry (Pharmacopsychiatry) Vol. 24 Issue 6 Pg. 229-31 (Nov 1991) ISSN: 0176-3679 [Print] Germany
• PMID: 1687486 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antipsychotic Agents
• Benzamides
• Monoamine Oxidase Inhibitors
• Moclobemide

Topics

• Akathisia, Drug-Induced
• Antipsychotic Agents (adverse effects, therapeutic use)
• Benzamides (therapeutic use)
• Depressive Disorder (drug therapy)
• Humans
• Male
• Middle Aged
• Moclobemide
• Monoamine Oxidase Inhibitors (therapeutic use)
• Psychomotor Agitation (drug therapy)